U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07398651) titled 'Apremilast and Adalimumab in Psoriatic Arthritis Patients' on Jan. 29.
Brief Summary: The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
Study Start Date: Dec. 30, 2026
Study Type: INTERVENTIONAL
Condition:
Psoriatic Arthritis
Ultrasound Assessment
TNF
Intervention:
DRUG: Adalimumab
PsA patients who will receive Adalimumab with methotrexate therapy for 3 months
DRUG: Apremilast
PsA patients who will receive Apremilast with methotrexate therapy for 3 months
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Tanta University
Information provide...